` BXRXQ (Baudax Bio Inc) vs S&P 500 Comparison - Alpha Spread

BXRXQ
vs
S&P 500

Over the past 12 months, BXRXQ has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +16% growth.

Stocks Performance
BXRXQ vs S&P 500

Loading
BXRXQ
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BXRXQ vs S&P 500

Loading
BXRXQ
S&P 500
Difference
www.alphaspread.com

Performance By Year
BXRXQ vs S&P 500

Loading
BXRXQ
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Baudax Bio Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Baudax Bio Inc
Glance View

Market Cap
44 USD
Industry
Pharmaceuticals

Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 80 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The firm is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.

BXRXQ Intrinsic Value
Not Available
Back to Top